Delivery Order SPE2DB20D2104-SPE2DB22FT78K
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,528.08 Firm Fixed Price Delivery Order is for the supply of RESTASIS 0.05% Eye Emulsion, a specialty ophthalmic medication. The award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,958.72 Delivery Order contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The award is associated with a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,758.57 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The award is not designated as a set-aside contract. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,001.84 Firm Fixed Price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription ophthalmic medication, with a period of performance through May 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,226.27 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a medication used to treat dry eye disease. The contract has a completion date of February 2, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,948.36 firm-fixed-price delivery order contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has an ultimate completion date of October 23, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award is for a delivery order placed by the Defense Logistics Agency (DLA) with Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,843.23 firm fixed-price contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty medication used to treat dry eye disease. The contract award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,402.40 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has an ultimate completion date of October 18, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,436.88 firm fixed-price delivery order is for RESTASIS 0.05% eye emulsion 30-count packages, with a completion date of December 4, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,471.20 Firm Fixed Price Delivery Order contract is for the supply of RESTASIS 0.05% Eye Emulsion 30s, a prescription ophthalmic medication. The contract has an ultimate completion date of January 8, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB22FT78KDelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,083.53 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a medication used to treat dry eye disease. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which enables the government to efficiently procure a range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has no set-aside designation, indicating open competition. In addition to the DLA IDC, AmerisourceBergen also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.1k | 8/30/22 |